Decamethoxine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Decamethoxine
Accession Number
DB13705
Description
Not Available
Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 693.92
Monoisotopic: 692.5025643
Chemical Formula
C38H74Cl2N2O4
Synonyms
  • Decamethoxin
External IDs
  • MM-692

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcenocoumarolThe risk or severity of bleeding can be increased when Decamethoxine is combined with Acenocoumarol.
DicoumarolThe risk or severity of bleeding can be increased when Decamethoxine is combined with Dicoumarol.
FluindioneThe risk or severity of bleeding can be increased when Decamethoxine is combined with Fluindione.
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Decamethoxine.
PhenindioneThe risk or severity of bleeding can be increased when Decamethoxine is combined with Phenindione.
PhenprocoumonThe risk or severity of bleeding can be increased when Decamethoxine is combined with Phenprocoumon.
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Decamethoxine.
Typhoid vaccineThe therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Decamethoxine.
Vibrio cholerae CVD 103-HgR strain live antigenThe therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Decamethoxine.
WarfarinThe risk or severity of bleeding can be increased when Decamethoxine is combined with Warfarin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

ATC Codes
D08AJ10 — Decamethoxine
Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
81I73K1HKN
CAS number
38146-42-8
InChI Key
LRQIWRXCHWNNEA-MWZFJMJKSA-L
InChI
InChI=1S/C38H74N2O4.2ClH/c1-29(2)33-21-19-31(5)25-35(33)43-37(41)27-39(7,8)23-17-15-13-11-12-14-16-18-24-40(9,10)28-38(42)44-36-26-32(6)20-22-34(36)30(3)4;;/h29-36H,11-28H2,1-10H3;2*1H/q+2;;/p-2/t31-,32-,33+,34+,35-,36-;;/m1../s1
IUPAC Name
{10-[dimethyl(2-{[(1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexyl]oxy}-2-oxoethyl)azaniumyl]decyl}dimethyl(2-{[(1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexyl]oxy}-2-oxoethyl)azanium dichloride
SMILES
[Cl-].[Cl-].CC(C)[[email protected]@H]1CC[[email protected]@H](C)C[[email protected]]1OC(=O)C[N+](C)(C)CCCCCCCCCC[N+](C)(C)CC(=O)O[[email protected]@H]1C[[email protected]](C)CC[[email protected]]1C(C)C

References

General References
Not Available
ChemSpider
52083646

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility3.1e-06 mg/mLALOGPS
logP3.06ALOGPS
logP0.74ChemAxon
logS-8.4ALOGPS
pKa (Strongest Basic)-7.5ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area52.6 Å2ChemAxon
Rotatable Bond Count21ChemAxon
Refractivity207.03 m3·mol-1ChemAxon
Polarizability79.51 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on June 23, 2017 14:47 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates